---
figid: PMC6589502__fig-2
figlink: /pmc/articles/PMC6589502/figure/f2/
number: <b>Figure 2.</b>
caption: Mutations and signaling pathways involved in LMs. Mutations in EPHB4 and
  NRAS lead to activate the signaling of RAS/MEK/ERK pathway. Mutations in PIK3CA
  and AKT lead to activate the signaling of PIK3/AKT/mTOR pathway. CLOVES, congenital
  lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal
  and spinal; EFNB2, ephrin-B2; EPHB4, ephrin B4; GLA, generalized lymphatic anomaly;
  LM, lymphatic malformation; mTOR, mammalian target of rapamycin; PIK3CA, phosphatidylinositol-4,5-bisphosphate
  3-kinase catalytic subunit alpha; PROS, PIK3CA-related overgrowth spectrum; RTK,
  receptor tyrosine kinase; VEGF-C, vascular endothelial growth factor-C; VEGFR, VEGF
  receptor.
pmcid: PMC6589502
papertitle: 'Generalized Lymphatic Anomaly and Gorham–Stout Disease: Overview and
  Recent Insights.'
reftext: Michio Ozeki, et al. Adv Wound Care (New Rochelle). 2019 Jun 1;8(6):230-245.
pmc_ranked_result_index: '19215'
pathway_score: 0.9642649
filename: fig-2.jpg
figtitle: 'Generalized Lymphatic Anomaly and Gorham–Stout Disease: Overview and Recent
  Insights'
year: '2019'
organisms: Homo sapiens
ndex: b22582ac-deb9-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6589502__fig-2.html
  '@type': Dataset
  description: Mutations and signaling pathways involved in LMs. Mutations in EPHB4
    and NRAS lead to activate the signaling of RAS/MEK/ERK pathway. Mutations in PIK3CA
    and AKT lead to activate the signaling of PIK3/AKT/mTOR pathway. CLOVES, congenital
    lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal
    and spinal; EFNB2, ephrin-B2; EPHB4, ephrin B4; GLA, generalized lymphatic anomaly;
    LM, lymphatic malformation; mTOR, mammalian target of rapamycin; PIK3CA, phosphatidylinositol-4,5-bisphosphate
    3-kinase catalytic subunit alpha; PROS, PIK3CA-related overgrowth spectrum; RTK,
    receptor tyrosine kinase; VEGF-C, vascular endothelial growth factor-C; VEGFR,
    VEGF receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KRAS
  - AKT1
  - HRAS
  - EFNB2
  - AKT3
  - MAPK3
  - AKT2
  - MAPK11
  - EPHB4
  - MAPK13
  - MAPK12
  - PIK3CA
  - PROS1
  - BRAF
  - RAF1
  - ARAF
  - MAPK9
  - MAPK14
  - MAPK1
  - MAPK8
  - MAPK10
  - MAP2K2
  - MAP2K1
  - MTOR
  - FLT4
  - GLA
  - NRAS
  - VEGFC
  - Pazopanib
  - ETrametinib
  - Sirolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: RAS/MAPK
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAS/MAPK
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: EFNB2
  symbol: EFNB2
  source: hgnc_symbol
  hgnc_symbol: EFNB2
  entrez: '1948'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: EPHB4
  symbol: EPHB4
  source: hgnc_symbol
  hgnc_symbol: EPHB4
  entrez: '2050'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: PIK3CA
  symbol: PIK3CA
  source: hgnc_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PROS
  symbol: PROS
  source: hgnc_prev_symbol
  hgnc_symbol: PROS1
  entrez: '5627'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: RAS/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: VEGFR3
  symbol: VEGFR3
  source: hgnc_alias_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: GLA
  symbol: GLA
  source: hgnc_symbol
  hgnc_symbol: GLA
  entrez: '2717'
- word: RAS/MAPK
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: VEGF-C
  symbol: VEGFC
  source: hgnc_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
chemicals:
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: ETrametinib
  source: ''
  identifier: ''
- word: Sirolimus
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
